Lauren Madigan, MD, shares open-label extension results demonstrating sustained improvements with avapritinib in patients ...
Collapsing the very-low-risk category reflects broader acceptance of active surveillance for Gleason 6 disease, while PARP ...
Nonsteroidal topicals like roflumilast are enabling proactive, long-term psoriasis control across a broad range of patients, ...
New research is shedding light on why many patients with chronic spontaneous urticaria (CSU) remain hesitant to adopt advanced treatments, even as newer biologic and targeted therapies show promise in ...
New FDA approvals and emerging trial data drive two pivotal 2026 NCCN guideline updates: lutetium-177 PSMA-617 for ...
The study, evaluating the efficacy of the combination of efgartigimod alfa and hyaluronidase-qvfc, is the first to ...
Combining traditional dermatopathology with PCR-based molecular testing improves diagnostic accuracy in differentiating eczema from psoriasis, particularly in ambiguous cases.
In addition to the US, high-dose nusinersen (Spinraza; Biogen) is also approved in the European Union, Japan, and Switzerland. The patients who received nusinersen exhibited a 15.1-point improvement ...
Melinda Gooderham, MD, MSc, FRCPC, discusses findings from the Latitude PsO 3001 and Latitude PsO 3002 studies evaluating zasocitinib. This content was developed independently and is not endorsed by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results